

Review Article

The Role of Long-Chain Fatty Acids in Inflammatory Bowel Disease

Chunxiang Ma ^{1,2}, Reshma Vasu,³ and Hu Zhang ^{1,2}

¹Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China

²Centre for Inflammatory Bowel Disease, West China Hospital, Sichuan University, Chengdu, China

³West China School of Medicine, Sichuan University, Chengdu, China

Correspondence should be addressed to Hu Zhang; zhanghu@scu.edu.cn

Received 23 August 2019; Accepted 3 October 2019; Published 3 November 2019

Academic Editor: Carla Sipert

Copyright © 2019 Chunxiang Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Inflammatory bowel disease (IBD) is a complicated disease involving multiple pathogenic factors. The complex relationships between long-chain fatty acids (LCFAs) and the morbidity of IBD drive numerous studies to unravel the underlying mechanisms. A better understanding of the role of LCFAs in IBD will substitute or boost the current IBD therapies, thereby obtaining mucosal healing. In this review, we focused on the roles of LCFAs on the important links of inflammatory regulation in IBD, including in the pathogen recognition phase and in the inflammatory resolving phase, and the effects of LCFAs on immune cells in IBD.

1. Introduction

Inflammatory bowel disease (IBD), comprising Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, remitted, and disabled inflammatory condition. Although several lines of evidence decipher the associated risk factors for IBD, it is still difficult to interpret the exact pathogenesis. However, regardless of the underlying etiopathogenesis, the sustained inflammation in the intestine does represent an important pathological feature for IBD [1]. Healthy intestinal mucosa depends on a complex inflammation-related equilibrium. Once the counterbalance is discomposed, the excessive pro-inflammatory cytokines will accelerate IBD progression. Therefore, using anti-inflammatory treatments to counteract the overproduction of intestinal proinflammatory cytokines represents the primary therapeutic approaches to control IBD aggravation. Currently, the ambition of the treatment scheme in IBD is to obtain mucosal healing [2]. The existing drug regimens to achieve this aim in IBD mainly include steroids, immunosuppressants, and biologics. Nonetheless, aside from the expensive medical expenditure, the side effects carried by these drugs also motivate doctors to develop other cheaper and more available therapeutic approaches. These

emerging treatments are expected to substitute or boost the current IBD therapies.

Long-chain fatty acids (LCFAs) have a reciprocal relationship with IBD. With industrialization development, the morbidity of IBD raises dramatically in developing countries, which could be ascribed to a marked shift in the dietary mode to a certain extent [3]. It is found that the increased incidence of IBD synchronizes with a western-oriented alimentary habit (a higher ratio of n-6/n-3 long-chain polyunsaturated fatty acids (PUFAs) and an abundance of saturated long fatty acids) [4]. To date, mounting epidemiology evidence indicates that LCFAs are crucial for the etiology of IBD. For instance, a prospective study analysis reveals that a higher ratio of n-3/n-6 long-chain PUFA intake keeps an inverse association with the IBD onset [5]. The beneficial role to maintain IBD remission with such dietary intervention is equal to the role observed in another prospective analysis [6]. Beyond the epidemiological relation, LCFAs are implicated in modulating intestinal damage on both the gross lesion and histopathological change. Hassan et al. [7] reported that the supplement of n-3 PUFAs could mitigate intestinal hyperemia, ulcerations, and necrosis in a relapsed colitis model, 2,4,6-trinitrobenzene sulfonic acid- (TNBS-)

induced rat colitis. Moreover, the fact that n-3 PUFAs restore mucosal architecture and ulceration was also manifested in an acute enteritis model, dextran sulfate sodium- (DSS-) induced mouse colitis [8]. In addition, gross intestinal health often is reflected by villus and crypt construction, which are essential for the protection of the intestinal epithelial barrier. Consistent with the mentioned findings, the supplementation of n-3 PUFAs was shown to ameliorate intestinal morphologic damage and increase villus height on a piglet model challenged by lipopolysaccharides (LPS) [9]. In contrast to n-3 PUFAs, n-6 PUFAs produce a significantly lower villus height than the control group, rather than improve mucosal morphology in total parenteral nutrition- (TPN-) related gut barrier impairment, indicating that n-6 PUFAs have a deteriorated effect on intestinal defense [10]. The detrimental movement of n-6 PUFAs on the gut is further replicated in the IBD animal model, in which n-6 PUFA application primes extensive depletion of goblet cells and overwhelming infiltration of leukocytes in the intestinal mucosa [11]. In conclusion, the wealth of evidence supports that various LCFAs have complex effects on intestinal inflammation and IBD.

Although a number of previous researches regarding LCFAs have been published, most investigations just deemed LCFAs as an essential nutrient in the regulation of energy metabolism. Nowadays, growing appreciations are starting to focus on their roles on inflammatory regulation in many diseases and are making endeavors to unravel the underlying mechanisms. In this review, we will provide a comprehensive insight into the mechanisms, by which LCFAs have an important role in regulating intestinal inflammation, especially in IBD, aimed at holding potential as targets for novel curative treatment.

2. LCFA Derivatives

LCFAs are defined as a sort of fatty acids with a carbon chain length of 13 to 21 carbons [12]. According to the number of double bonds, LCFAs could be again subdivided into saturated (no double bond), monounsaturated (one double bond), or polyunsaturated fatty acids (more than two double bonds). Accumulating studies demonstrate that oleic acid of monounsaturated fatty acids (MUFAs) imbues a beneficial effect on intestinal inflammation in IBD [13, 14]. However, the roles of PUFAs on intestinal inflammation tend to be perplexing. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), rich in fish oil, are precursors for n-3 PUFAs and are categorized with n-6 PUFA-derived arachidonic acid (AA) as important lipid mediators in immune regulation and inflammation. Conventionally, n-6 PUFAs are involved in the proinflammatory effect because linoleic acid (LA, n-6 PUFAs) can be metabolized into AA, which by the cyclooxygenase (COX) pathway form prostaglandins (PGs), thromboxanes (TXs), and leukotrienes (LTs) (a series of inflammatory mediators with pleiotropic functions). In contrast, n-3 PUFAs seem to facilitate inflammatory regulation, for which α -linolenic acid (ALA, n-3 PUFAs) can be converted into EPA and DHA, in which the two sorts of PUFAs compete with the synthesis of each one [15]. Therefore, the

disruption of a suitable n-6/n-3 PUFA rate will favor ongoing inflammation. It is not probable to only consider the role of one fatty acid within the inflammatory process without considering the functions of another fatty acid.

Inflamed colonic mucosa in UC patients is characterized by a higher concentration of AA and a lower concentration of the EPA [15]. The higher content of AA competes with the same mechanism shared by n-3 PUFAs and then enhances LA-associated proinflammatory components, which is consistent with the inflammatory severity of intestinal mucosa. Additionally, studies from TNBS-induced mouse colitis have also shown that an n-3 PUFA diet decreases COX-2 expression and LTB₄ production in the colon [16]. It is not hard to understand that any exacerbated gut inflammatory in IBD tips the inflammatory homeostasis shifting to the proinflammatory side. Moreover, plant-derived oils rich in ALA, rather than fish-derived ALA, were supported on the TNBS rat model with a prominent effect of downregulating COX2 mRNA levels rather than fish-derived ALA [17]. Since plant-derived n-3 PUFAs are a cheaper and more accessible source and are superior to reduce intestinal inflammation, this type of n-3 PUFAs should be prescribed widely in IBD patients.

3. Regulation of LCFAs in the Inflammatory Process

The key steps of the inflammatory process can be generally classified as three interconnected and sequential phases: (i) the pathogen recognition phase, in which pathogens penetrate the epithelial barrier or bond to receptors; (ii) the mobilization phase, in which immune cells immigrate from blood to the tissue, a process promoted by adhesion molecules and chemoattractants; and (iii) the resolution phase, in which harmful agents are eliminated by anti-inflammation mediators. The successful inflammatory response is crucial to control, or at least limit aggression, and aid to the repair of intestinal injury. As the discussion below, LCFAs are responsible for each of these phases to participate in the inflammatory process of IBD.

3.1. Effects of LCFAs in the Pathogen Recognition Phase. The pathogen recognition phase is part of intestinal immune response, which depends on the innate sensors on the intestinal epithelial cell, such as pattern recognition receptors (PRRs). They quickly recognize pathogen components and systemically and/or locally influence inflammatory transcription factors. A tailored activation of transcription factors is vital to intestinal barrier function. LCFAs involve in this phase to regulate intestinal inflammation in IBD (Table 1).

The intestinal barrier is the first line of gut defense against bacteria and other microorganisms. Intestinal epithelial cells and tight junctions in between them shape a physical barrier to contact with extrinsic factors as well as to maintain tissue homeostasis. Tight junction proteins, such as occludin, claudins, zona occludens- (ZO-) 1, and junctional adhesion molecules, are proven to be the main component of tight junctions (TJs). Aside from the physical barrier, the chemical barrier, constituted by intestinal mucins (MUCs), containing

TABLE 1: Effects of LCFAs in the pathogen recognition phase in IBD.

Pathogen recognition phase	The type of LCFAs	Role
Intestinal barrier	DHA and EPA	Protect the tight junctions while reducing MUC2 secretion
	Palmitic acid and palm oil	Promote MUC2 secretion
	n-6 PUFAs	Reduce MUC2 secretion
	n-3 PUFAs	Upregulate TLR-2 gene
	n-9 PUFAs	Upregulate TLR-4 gene
TLR/NOD pathway	ALA	Inhibit the mRNA expression of TLR4, downregulate proinflammatory cytokines, upregulate anti-inflammatory cytokines, and decrease the mRNA expression of NOD
NF- κ B pathway	Fish oil	Downregulate the NF- κ B pathway
	ALA, EPA, and DHA	Downregulate the NF- κ B pathway
	Oleic acid	Downregulate the NF- κ B pathway
PPAR- γ pathway	Conjugated linoleic acid	Upregulate the PPAR- γ pathway
	DHA and EPA	Upregulate the PPAR- γ pathway

antimicrobial peptides and secretory immunoglobulins (sIg), is also important in the prevention of intestinal pathogen invasion [18]. In IBD pathogenesis, the susceptibility to intestinal inflammation and the severity of gut lesions will be sharpened due to the dysfunction of TJ molecules or mucus layer. Recently, dietary DHA and EPA have been demonstrated to maintain intestinal barrier function in IL-10-deficient mice by rescuing the expression of occludin and ZO-1 [19]. The protective role could attain optimization by application with phospholipid DHA to restore intestinal barrier [20]. Additionally, this favorable effect of n-3 PUFA acts in a concentration-dependent manner. Various concentrations of n-3 PUFAs were used by Beguin et al. [21] to incubate Caco-2 cells, a model of human intestinal barrier. The 30 mM DHA did not affect any component of intestinal barriers, while when the concentration reached 150 mM, ZO-1 intensity was increased. Incubation with n-6 PUFAs lowering the intensity of occludin also was found in this research. To determine the effect of LCFAs on MUC2 production, a subsequent team [22] applied a large scale of fatty acids, including saturated LCFAs, MUFAs, and PUFAs, to stimulate human colonic mucus-secreting HT29-MTX cells in vitro and rats in vivo. Only saturated LCFAs (palmitic acid and palm oil) were involved in the upregulation of MUC2 production in two kinds of experiments; the other types of fatty acids led to MUC2 reduction. Collectively, DHA and EPA serve as protectors for the gut barrier in IBD due to their ability to recover the TJ-related elements, together with certain saturated LCFAs strengthening MUC2 secretion. In contrast, n-6 PUFAs impair the structure to facilitate intestinal inflammation. Considering the difference between the animal model and human body, further researches are required to explore these mechanisms in IBD patients and identify the optimum concentration.

PRRs receive the information from various pathogens and danger sensors and initiate intestinal inflammation. As members of PRRs, toll-like receptors (TLRs) play crucial roles in immune response by recognizing the accessory structures of pathogen molecules. The associations between TLRs and LCFAs in intestinal inflammation have been confirmed

in experimental colitis. Evidence indicates that n-3 PUFAs and n-9 PUFAs, respectively, upregulate the TLR-2 and TLR-4 genes of TNBS-induced colitis, while n-6 PUFAs influence high-mobility group box 1 (HMGB1), a reactivator of TLR gene [16]. An ALA-rich diet also activates genes that encode inhibitors of TLR signaling, IL-1 receptor-associated kinase 1 (IRAK1), which is a negative regulator of TLR and IL-1 receptor signaling [23]. On the transcriptional level, this supplement could not only inhibit the mRNA expression of TLR4 but also regulate the downstream inflammatory cytokines in the colitis model, containing the downregulation of proinflammatory cytokines IL-1 β , IL-6, and TNF- α and the upregulation of anti-inflammatory cytokine IL-10. It is well accepted that a superiority level of IL-1 β , IL-6, TNF- α , and IL-8 means a common feature of many inflammatory conditions, including IBD [24]. What is more, this research indicates that n-3 PUFAs inhibit transcription factors downstream of the TLR-associated factor 6 pathway. Similar to TLR4, the nucleotide-binding oligomerisation domain (NOD) family, another PRR, participates in the modulation of inflammatory response through nuclear factor kappa B (NF- κ B) activation and inflammasome formation, in which the later component leads to the maturation of proinflammatory cytokines, such as IL-1 β and IL-18 [25, 26]. Oil-rich ALA is indicated to decrease the abundance of mRNA of NOD on a model of intestinal injury, subsequent to exerting protection for intestinal integrity and barrier function [9]. These researches indicate that n-3 PUFAs confer intestinal inflammation with a protective effect for downregulating TLR/NOD pathways. In contrast, saturated fatty acid and n-6 PUFAs fail to improve intestinal inflammation, even disrupt the intestinal barrier by upregulating TLR/NOD pathways [27]. In addition, TLR4 has been reported to have a higher expression on intestinal epithelial cells (IECs) in IBD patients than control individuals [28], along with the fact that NOD has been the first identified susceptibility gene for IBD. It suggests that a high content of n-3 PUFAs virtually exerts beneficial effects on IBD-related inflammation via TLR4/NOD signaling pathways. Some noteworthiness should be paid on the conflicting effect of TLR blocker on

TABLE 2: Effects of LCFAs on immunity cells in IBD.

Effects of LCFAs on immune cells	The type of LCFAs	Role
Neutrophils	n-6 PUFAs	Inhibit neutrophil infiltration
	DHA and EPA	Inhibit neutrophil infiltration
	n-3 PUFAs	Avert the concomitant hurt caused by neutrophil production
Dendritic cells	n-3 PUFAs	Reduce the antigen-presenting ability of DCs
	PGE2	Promote the antigen-presenting ability of DCs
	Palmitic acid and oleic acid	Reduce the immune response ability of B cells
B cells	n-3 PUFAs	Reduce the immune response ability of B cells, promote intestinal sIgA secretion
	DFO	Reduce the percentage of CD8+ cells, diminish the expression of CD69 on CD4+ T cells, and increase the count of FoxP3+ CD25+ T cells
T cells	n-3 PUFAs	Reduce the activated cytokines of Th17 cells
	Eicosanoids	Decrease the percentage of Th17 cells

intestinal inflammation. TLR4 blockers are declared to have beneficial effects on acute gut inflammation, while it is known as an impeder for intestinal mucosal healing in DSS-induced colitis [29]. Acting as the agonist or antagonist for TLR/NOD, LCFAs are needed to be further studied in IBD regarding long-term prognosis.

NF- κ B is an important component of TLR/NOD signaling pathways. Typically, the inactive NF- κ B is anchored in the cytoplasm with I κ B (inhibitor of NF- κ B), which impedes NF- κ B bonding to its nuclear localization sequence (NLS). Once stimulated, I κ B will be phosphorylated, and the transcription of the targeting gene will be initiated following NF- κ B entering the nucleus [30]. Furthermore, this paradigm will augment the levels of proinflammatory cytokines to cause severe intestinal inflammation in IBD, including COX-2, IL-1b, and IL-6 in acute inflammatory status, as well as CXCL12 and CXCL13 in the chronic inflammatory state [31, 32]. In fact, LFCAs can act on the expression of NF- κ B on immunity cells to affect the inflammatory launching. Fish oil-fed mice are displayed with a decreased production of TNF, IL-1 β , and IL-6 on endotoxin-stimulated macrophages [33, 34], which is beneficial to IBD intestinal inflammation. Besides, ALA, EPA, and DHA were demonstrated to reduce the expression of TNF- α , LTB4, and COX-2 by inhibiting NF- κ B activity in rats with TNBS-induced colitis [7]. In contrast, oleic acid (n-9 PUFAs) is not documented to exert a suppressive effect on colitis activity through this pathway [35]. Furthermore, after adding n-3 PUFA to conventional treatment (5-ASA), a lower NF- κ B activation can be observed in TNBS-induced colitis, which provides a cogent explanation for the favorable effects of n-3 PUFAs on intestinal inflammation. However, whether the addition of n-3 PUFA can assist the curative effects of other IBD standard treatments is not yet revealed. So, numerous potential investigations and studies are warranted to be performed in the future.

Peroxisome proliferator-activated receptor- (PPAR-) γ is another component of the TLR/NOD signaling pathway. As a transcription factor, PPAR- γ interferes with the translocation of NF- κ B to the nucleus and then executes an indispensable anti-inflammatory role. The impaired PPAR- γ level was

confirmed on intestinal mucosa both in IBD patients and animal models. At present, numerous PPAR- γ agonists have been applied in the clinical practice to treat IBD patients, for example, the commonly used 5-aminosalicylic acid (a known PPAR- γ agonist) [36]. The LCFAs have also emerged as important regulators of PPAR- γ expression, providing another important treatment option for IBD patients. Conjugated linoleic acid (CLA) can ameliorate DSS colitis through the repression of TNF- α expression and NF- κ B activation and the induction of PPAR- γ [37]. Another study presumed that CLAs, as a supplement with probiotics (VSL#3), could be more effective to control intestinal inflammation through the activation of PPAR- γ [38]. To further verify the regulation mechanism of PPAR- γ on colitis, Bassaganya-Riera et al. [39] found that the beneficial effect of CLA and VSL#3 in mice with DSS colitis depended on PPAR- γ in myeloid cells. The loss of PPAR- γ in myeloid cells would abrogate such protective effect. CLA was also shown in the clinical trial to ameliorate intestinal inflammation. In an open-label study, after a period of 12 weeks of administration with CLA, PPAR- γ on peripheral blood CD4+ and CD8+ T cell in mild to moderately active CD patients were conspicuously repressed, along with a prominent descent of the CD activity index from 245 to 187 [40]. Regarding the effectiveness of LCFAs in regulating PPAR- γ expression, Marion-Letellier et al. [41] investigated that DHA and EPA could even attain the similar role of troglitazone on PPAR- γ in Caco-2 cells. These findings show that the induction and activation of CLAs, DHA and EPA, which act as PPAR- γ agonists, indeed contribute to the abrogation of intestinal inflammation in IBD.

3.2. Effects of LCFAs on Immunity Cells. Inflammatory mediators produced in the acute phase, such as TNF- α and IL-1 β , upregulate the transcription of chemokine genes, which subsequently recruit immune cells from intravascular blood into inflamed areas. IBD is a complex disease accompanied by prominent infiltration of inflammatory cells, including T lymphocytes, macrophages, neutrophils, mast cells, and plasma cells. LCFAs have been implicated in the regulation of immune cells in IBD (Table 2).

Neutrophils are the first type of inflammatory cells to transmigrate endothelial cells and infiltrate to inflammatory foci, where neutrophils differentiate into polymorphonuclear (PMN) and macrophages. The transmigration process is promoted by the formation of chemokine gradients and the upregulation of adhesion molecules, in which intercellular adhesion molecule-1 (VCAM-1) and vascular cell adhesion molecule-1 (ICAM-1) are key molecules. As the extent of PMN infiltration in intestinal mucosa exhibits a correlation with the severity of IBD, weakening the production of chemoattractants and adhesion molecules is an ideal approach to control IBD intestinal lesions [42]. Cumulative studies demonstrate the anti-inflammatory properties of LCFAs acting in this manner on experimental colitis models. The n-6 PUFAs downregulate the expression of chemoattractant production C-X-C motif ligand-1 (CXCL1) and C-C motif ligand-2 (CCL2) on intestinal ischemia/reperfusion injury [43], as well as n-3 PUFAs inhibit chemokine production such as interleukin-8 (also known as CXCL8) [41]. Meanwhile, the beneficial effects of n-3 PUFAs are also confirmed in vivo that both DHA and EPA trigger a reduction of VCAM-1 and ICAM-1 to inhibit PMN transepithelial migration in TNBS mice [44]. Notably, the excessive production of activated neutrophils not only eradicate invading pathogens but also cause extravascular tissue damage. The detrimental effect has been associated with an increased production of cytotoxic reactive oxygen and nitrogen species and lytic enzymes. This collateral damage can be avoided by treatment with n-3 PUFAs, which decreases the level of serum LTB₄ released from neutrophils in UC patients [45]. In conclusion, both n-3 PUFAs and n-6 PUFAs could participate in the regulation of neutrophil infiltration, and n-3 PUFAs could avert the concomitant hurt caused by neutrophil production in IBD.

Dendritic cells (DCs) are an intermediate linker between the identified exogenous information and T lymphocytes, which is required for the attachment of ICAM-1 on DCs to lymphocyte function-associated antigen-1 (LFA-1) on T cells. Once major histocompatibility complex class-II (MHC-II) molecules on DCs bind to antigen receptors (TCRs) on T cells, accompanied by the combination of cofactors, such as CD80 and CD86 on DCs and CD28 and CTLA-4 on T cells, the antigen-related information will be conveyed. Many studies suggest that the functions of DCs can be modulated by LCFAs via adjusting these cell surface molecules. On the one hand, n-3 PUFAs could suppress the expression of CD69 and CTLA-4 on T lymphocytes that reduces DC immunity response [46, 47]. On the other hand, LCFAs were found to downregulate the MHC-II expression on intestinal DCs, thereby reducing the antigen-presenting ability of DCs [48]. In contrast, n-6 PUFA-derived PGE₂ extends the level of costimulatory molecules both on DCs and T cell, including OX40 and CD70, and induces T cell proliferation [49, 50]. Therefore, it is easy to infer that the antigen presentation of DCs is protected by n-6 PUFAs series rather than n-3 PUFAs series. Kanai and Watanabe [51] posited that these findings shed light on the development of an implacable strategy to treat IBD. However, with different affinities to costimulatory factors, various LCFAs

have different degrees of influence on DC function. Moreover, the effect of LCFAs on DC function varies from intestinal inflammatory conditions. Therefore, for LCFAs targeting DCs in IBD, these aspects need to be carefully explored in future trials.

B cells are another antigen-presenting cell type with unique secretory function. The key aspects of B cell function have been reported to be regulated by LCFAs in a steady accumulation of data. In terms of B cell activation, using palmitic acid, oleic acid, and n-3 PUFAs to deal with B cells for 48 hours, the CD69 expression of the activation marker of B cells is lowered more than 40% by palmitic acid and oleic acid, while it is not influenced by n-3 PUFAs [52]. However, n-3 PUFAs are demonstrated to influence the B cell lipid raft microdomain clustering to alter B cell function. Such altered organization of the lipid membrane keeps the line with B cell function by changing transmembrane signaling [53]. Furthermore, Gurzell et al. [54] identified this mechanism of n-3 PUFAs in a colitis-prone mouse model. After feeding mice with a diet rich in n-3 PUFAs for five weeks, they examined B cells extracted from the spleen and discovered modifying lipid composition on the B cell membrane, upregulating the activation marker of B cells, as well as arising fecal sIgA. The same function on intestinal sIgA is replicated in a palmitic acid diet [55]. As we mentioned above, sIgA is essential for the intestinal mucus barrier, whose hypersecretion contributes to pathogen defense in IBD. However, analysis from IBD patients demonstrates that intestinal B cells are likely to dominate pathogenic influence on intestinal immunity. Rectal mucosa of UC patients has shown increased B cell activation versus the healthy control [56]. Eosinophilic recruitment in IBD is also reported to take place owing to the accumulating chemokines brought by B cell activation [57]. Given the current gap in the reports about the functions of dietary n-3 PUFAs on B cells among IBD patients, the related studies should apply more focus on the bidirectional regulation of B cells on intestinal immunity in vivo.

T cells and their productions are documented in the pathogenesis of IBD. One type of T cell is CD4⁺ T cell, including T helper (Th) 1, Th2, Th17, and regulatory T cells (Tregs), collectively belonging to antigen-presenting cells. Another type of T cell is the terminal effector of antigen-presenting cells, CD8⁺ T cell [58]. LCFAs may involve in IBD pathogenesis via influencing these cell subsets. When using *Helicobacter hepaticus* to infect SMAD3^{-/-} mice, an inflammatory colitis model, and then feeding these mice with dietary fish oil (DFO) for eight weeks, Woodworth et al. [59] detected a higher infiltration of the inflammatory cell on cecum and colon tissues than those just infected with *H. hepaticus*. Moreover, these mice even appear to display emerging dysplastic crypts and mitotic figures on colon and cecum tissues. Meanwhile, the consumption of DFO reduces the percentage of CD8⁺ cell, diminishing the expression of CD69 on CD4⁺ T cell and increasing the count of FoxP3⁺ CD25⁺ T cells. However, the results from other teams suggest that the role of n-3 PUFAs on colitis depends on inflammatory types and sites. These groups used n-3 PUFAs to deal with acute or chronic animal models of intestinal inflammation and found that there is no difference concerning the

TABLE 3: Effects of LCFAs in the resolving phase in IBD.

Resolving phase	The type of LCFAs	Role
Neutrophil trafficking	RvE1, RvD2, LXA4, and MaR1	Inhibit PMN infiltration
	Resolvins from n-6 and n-3 PUFAs	Promote phagocytosis of macrophages, polarize macrophages towards M2 phenotype
Apoptosis and phagocytosis	RvD1	Promote phagocytosis of apoptotic macrophages
	LXA4	Promote phagocytosis of apoptotic macrophages and neutrophils
	RvE1	Promote phagocytosis of apoptotic neutrophils
	Protectin D1	Promote phagocytosis of apoptotic neutrophils

proportion of Th17 cells between colonic lamina propria and spleen in the acute model of intestinal inflammation. However, Th17 cells located in colonic mucosa express lower activated cytokines and higher suppressive cytokine in the chronic model of intestinal inflammation [60, 61]. Therefore, the series of n-3 PUFAs would be beneficial in chronic intestinal inflammation but could be harmful in acute intestinal inflammation. Regarding n-6 PUFAs, such dependent role was also implicated in the animal IBD model [62]. Moreover, reducing n-6 PUFA-derived eicosanoids decreases the percentage of Th17 cells in TNBS-induced colitis [63]. However, various ratios of LCFAs have different effects on Th/Treg balance in the IBD model [64]. Future studies should establish an optimum proportion of LCFA consumption for skewing T cell differentiation towards the production of the anti-inflammatory Treg cell subset, particularly in IBD patients.

3.3. Effects of LCFAs in the Inflammatory Resolving Phase.

The inflammatory resolving phase is a transitional process from the inflammatory response stage to the inflammatory self-limiting stage. Once the transition fails to conduct, the inflammatory homeostasis will be disrupted, and negative physiologic sequelae will occur. Such is the case in IBD, a disease mediated by chronic intestinal inflammation leading to intestinal stenosis. A plethora of recent studies have shown that specialized proresolving lipid mediators (SPM) have pleiotropic actions in response to prevent excessive inflammatory events and promote recurrent tissue homeostasis in IBD (Table 3). n-3 PUFA-derived metabolites are precursors of most SPM, including resolvins (Rvs), protectins, and maresins (MaR), while lipoxin is derived from AA. Among them, Rvs are nominated as RvE and RvD, respectively, from EPA and DHA. These chemical mediators are served as the components of mediating resolution and are coupled with multiple capacities that block neutrophil trafficking, induce phagocytosis, and clear apoptotic cells [65]. Thus, the implications of PUFA-derived SPM could promote inflammatory resolving.

Preventing the entrance of PMN cells into inflammatory sites is one of the proresolving properties of SMP. RvE1 is described as a prohibitor to transendothelial migration of PMN as well as a promoter to IL-12 [66]. With a higher concentration than RvE1 in the human body, RvD2 is equivalent to inhibit PMN infiltration, which relies on the elevated expression of G protein-coupled receptor 18 (GPR18) on PMN [67]. This blocking role also occurs for lipoxin A4 (LXA4) by stopping transendothelial migration of PMN

across the blood vessel endothelium along with promoting their clearance from inflammatory sites, which are facilitated by activating human LXA4 receptor (ALXR) to govern gene expression [68]. Additionally, MaR1 significantly reduces the PMN in inflammatory organs without altering PMN in peripheral blood, suggesting a crucial regulating role of MaR1 on PMN entry into inflammatory sites [69]. Taken together, SMP triggers the resolution program to combat the spread of inflammation by timely inhibiting PMN entrance. However, since SMP has protective properties for inflammation through binding to its receptors on PMN, further investigations are warranted to identify the exact receptors on PMN, and other novel receptors have yet to be explored.

Macrophage phagocytosis refers key components to clear apoptotic immune cells from the inflammatory region and to bring the inflamed intestine to tissue repairment and regeneration [70]. Resolvins from n-6 PUFAs as well as n-3 PUFAs not only support the phagocytosis of macrophages but also polarize macrophages towards M2 phenotype, a type of pro-resolution macrophages. Both resolvins intraperitoneally injected significantly ameliorate body weight loss, colon epithelial damage, and macrophage infiltration of the DSS colitis model [71]. The latest research delineates the SMP role on macrophage autophagy by treatment of murine and human macrophages with LXA4 and resolvin D1 (RvD1), which induces an obvious formation of autophagosomes and favors the fusion of the autophagosomes with lysosomes, thus attributing to phagocytosis of apoptotic macrophages [72]. Additionally, LXA4 and its analogs can clear the excessive infiltration of neutrophils via enhancing the monocyte-derived macrophage phagocytosis role on apoptotic neutrophils [73]. RvE1 strengthens macrophage efferocytosis of apoptotic PMN and additionally grants nonapoptotic PMN in lymph nodes and the spleen with phagocytosed zymosan [74]. Moreover, RvD1 is indicated to enhance macrophage efferocytosis by binding with either the lipoxin receptor or the orphan GPR32 on PMN [75]. LXA4, RvE1, and protectin D1 have collectively been verified to upregulate the expression of C-C chemokine receptor 5 on apoptotic neutrophils, which is related to blocking chemokine signaling [76]. To sum up, these results emphasize that LFAC derivatives may have therapeutic potential to orchestrate the elimination of sustained inflammation by stimulating the formation of autophagosomes and the phagocytosis of apoptotic PMNs. In consideration of the fact that autophagy is an important factor in the pathogenesis of IBD, LFAC derivatives aimed

at autophagy represent alternative therapeutic approaches for this chronic disease.

Recently, the vast findings are evidenced to reveal that the potential mechanisms would be indispensable for SPM in animal models of IBD. In the progression of the disease with a mouse model of DSS-induced acute intestinal injury, the precursor of protectin D1 was presented with an increase over 3-fold in the recovery phase than its original level [77]. The DPA-derived protectin and resolvin were shown to dampen intestinal inflammation and leukocyte adhesion in the mouse model of colitis. The endothelial monolayer of the human intestine administered with DPA-derived D-series protectin and resolvin also had lower cell adhesion response to TNF- α challenge compared with controls [8]. A study administrated with aspirin-triggered RvD1 (AT-RvD1) and RvD2 reported a reduced generation of IL-1 β , CXCL1, NF- κ B, VCAM-1, and ICAM-1 in DSS- and TNBS-induced colitis. Both AT-RvD1 and RvD2 exposure additionally decrease the disease activity index, improve intestinal pathological changes, and inhibit polymorphonuclear infiltration in both experimental colitis models [78]. Colitis models treated with DPA-derived maresin 1 by Marcon et al. [79] had also been demonstrated with significantly decreased levels of inflammatory cytokines, including IL-1 β , IL-6, IFN- γ , and TNF- α in DSS-induced colitis protocol, as well as IL-1 β and IL-6 in the TNBS-induced colitis protocol. Moreover, in LPS-stimulated bone marrow-derived macrophage, MaR1 provides significant protection against neutrophil migration and reactive oxygen species production by upregulating mannose receptor C, type 1 mRNA expression. For these reasons, the SPM from n-3 PUFAs and n-6 PUFAs promotes an inflammatory resolving milieu, which provides useful alternative therapeutic approaches to control chronic inflammation in IBD. In the subsequent studies, expanding our understanding of resolving molecules in IBD patients are warranted to be performed in the future.

4. Fatty Acid Receptors as Drug Targets for IBD

A steady accumulation of studies shows the strong relationship between fatty acids (FAs) and specific receptor proteins, G protein-coupled receptors (GPCRs). The FA-related GPCRs were previously named as GPR40, GPR43, GPR41, and GPR120, correspondingly renamed to Free Fatty Acid receptor (FFA) 1, FFA2, FFA3, and FFA4 [80]. FFA2 and FFA3 are recognized by and respond to short-chain fatty acids (SCFAs), whereas FFA1 and FFA4 are activated by LCFAs. Moreover, GPR84 has been reported as another receptor for MCFAs [81]. Although a number of FFA receptor antagonists or agonists have been identified to date, only both GPR84 and FFA2 receptor antagonists have been taken into the clinical practice in IBD. GLPG0974, as the first FFA2 antagonist to treat IBD patients, reduces the neutrophil activation and infiltration in the phase I clinical trial [82] but shows no differences in clinical responses, histopathology scoring, and Mayo score in mild to moderate UC patients [83]. The GPR84 antagonist, GLPG1205, is also terminated in the phase II trial due to the same reason [83]. Additionally, the selective FFA1 and FFA4 agonists as pharmacological

tools have mainly been developed and applied in diabetes [84, 85]. However, although the FFA1 and FFA4 are abundant in the intestine, especially in the colon [86], both agonists constituting unique and novel treatments for IBD have not been investigated. Furthermore, the modest ligand affinity of fatty acid agonists on its corresponding receptors obstructs their clinical application. Developing selective synthetic ligands to improve affinity and translating therapeutic targeting to yield real benefits for patients are imperative.

5. Conclusion

LCFAs have dual actions on intestinal inflammation in IBD by influencing the phase of pathogenic recognition and the infiltration and function of immune cells, along with the phase of inflammatory resolving. The mechanisms comprise the fact that LCFAs protect or dampen intestinal barriers, promote or inhibit TLR/NOD signaling pathways, and influence the balance between proinflammatory transcription factor NF- κ B and anti-inflammatory transcription factor PPAR- γ . Cumulative studies are utilizing LCFAs to access the remission of intestinal inflammation in IBD, both in IBD patient studies and animal experiments. Although the underlying signaling pathways have yet to be fully explored, the advantages of LCFA administration to facilitate the limitation of intestinal inflammation have been reflected by these studies. The aptitude of mucosal healing in IBD calls for development of new drugs. Administration of LCFAs should indeed be served as a useful therapeutic approach to treat IBD patients for its availability and effectivity.

Conflicts of Interest

There is no conflict of interest.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant Number: 81570502) and by the 1.3.5 Project for Disciplines of Excellence, West China Hospital, Sichuan University (Grant Number: ZYJC18037).

References

- [1] A. Kaser, S. Zeissig, and R. S. Blumberg, "Inflammatory bowel disease," *Annual Review of Immunology*, vol. 28, no. 1, pp. 573–621, 2010.
- [2] F. Rieder, T. Karrasch, S. Ben-Horin et al., "Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing," *Journal of Crohn's and Colitis*, vol. 6, no. 3, pp. 373–385, 2012.
- [3] N. A. Molodecky, I. S. Soon, D. M. Rabi et al., "Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review," *Gastroenterology*, vol. 142, no. 1, pp. 46–54.e42, 2012.
- [4] R. Marion-Letellier, G. Savoye, P. L. Beck, R. Panaccione, and S. Ghosh, "Polyunsaturated fatty acids in inflammatory bowel diseases," *Inflammatory Bowel Diseases*, vol. 19, no. 3, pp. 650–661, 2013.

- [5] A. N. Ananthkrishnan, H. Khalili, G. G. Konijeti et al., “Long-term intake of dietary fat and risk of ulcerative colitis and Crohn’s disease,” *Gut*, vol. 63, no. 5, pp. 776–784, 2014.
- [6] K. Uchiyama, M. Nakamura, S. Odahara et al., “N-3 polyunsaturated fatty acid diet therapy for patients with inflammatory bowel disease,” *Inflammatory Bowel Diseases*, vol. 16, no. 10, pp. 1696–1707, 2010.
- [7] A. Hassan, A. Ibrahim, K. Mbodji et al., “An α -linolenic acid-rich formula reduces oxidative stress and inflammation by regulating NF- κ B in rats with TNBS-induced colitis,” *Journal of Nutrition*, vol. 140, no. 10, pp. 1714–1721, 2010.
- [8] T. Gobetti, J. Dalli, R. A. Colas et al., “Protectin D1n-3 DPA and resolvin D5n-3 DPA are effectors of intestinal protection,” *Proceedings of the National Academy of Sciences*, vol. 114, no. 15, pp. 3963–3968, 2017.
- [9] H. Zhu, H. Wang, S. Wang et al., “Flaxseed oil attenuates intestinal damage and inflammation by regulating necroptosis and TLR4/NOD signaling pathways following lipopolysaccharide challenge in a piglet model,” *Molecular Nutrition & Food Research*, vol. 62, no. 9, 2018.
- [10] J. Wang, F. Tian, H. Zheng et al., “N-3 polyunsaturated fatty acid-enriched lipid emulsion improves Paneth cell function via the IL-22/Stat3 pathway in a mouse model of total parenteral nutrition,” *Biochemical and Biophysical Research Communications*, vol. 490, no. 2, pp. 253–259, 2017.
- [11] K. V. K. Reddy and K. A. Naidu, “Maternal and neonatal dietary intake of balanced n-6/n-3 fatty acids modulates experimental colitis in young adult rats,” *European Journal of Nutrition*, vol. 55, no. 5, pp. 1875–1890, 2016.
- [12] W. M. N. Ratnayake and C. Galli, “Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper,” *Annals of Nutrition & Metabolism*, vol. 55, no. 1–3, pp. 8–43, 2009.
- [13] P. S. A. de Silva, R. Luben, S. S. Shrestha, K. T. Khaw, and A. R. Hart, “Dietary arachidonic and oleic acid intake in ulcerative colitis etiology: a prospective cohort study using 7-day food diaries,” *European Journal of Gastroenterology and Hepatology*, vol. 26, no. 1, pp. 11–18, 2014.
- [14] C. Carrillo, M. Cavia Mdel, and S. Alonso-Torre, “Role of oleic acid in immune system; mechanism of action; a review,” *Nutricion Hospitalaria*, vol. 27, no. 4, pp. 978–990, 2012.
- [15] D. S. Pearl, M. Masoodi, M. Eiden et al., “Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity,” *Journal of Crohn’s and Colitis*, vol. 8, no. 1, pp. 70–79, 2014.
- [16] C. Charpentier, R. Chan, E. Salameh et al., “Dietary n-3 PUFA may attenuate experimental colitis,” *Mediators of Inflammation*, vol. 2018, Article ID 8430614, 10 pages, 2018.
- [17] R. Reifen, A. Karlinsky, A. H. Stark, Z. Berkovich, and A. Nyska, “ α -Linolenic acid (ALA) is an anti-inflammatory agent in inflammatory bowel disease,” *The Journal of Nutritional Biochemistry*, vol. 26, no. 12, article S0955286315002004, pp. 1632–1640, 2015.
- [18] Y. Kurashima and H. Kiyono, “Mucosal ecological network of epithelium and immune cells for gut homeostasis and tissue healing,” *Annual Review of Immunology*, vol. 35, no. 1, pp. 119–147, 2017.
- [19] J. Zhao, P. Shi, Y. Sun et al., “DHA protects against experimental colitis in IL-10-deficient mice associated with the modulation of intestinal epithelial barrier function,” *British Journal of Nutrition*, vol. 114, no. 2, pp. 181–188, 2015.
- [20] W. Cao, C. Wang, Y. Chin et al., “DHA-phospholipids (DHA-PL) and EPA-phospholipids (EPA-PL) prevent intestinal dysfunction induced by chronic stress,” *Food & Function*, vol. 10, no. 1, pp. 277–288, 2019.
- [21] P. Beguin, A. Errachid, Y. Larondelle, and Y. J. Schneider, “Effect of polyunsaturated fatty acids on tight junctions in a model of the human intestinal epithelium under normal and inflammatory conditions,” *Food & Function*, vol. 4, no. 6, pp. 923–931, 2013.
- [22] B. Benoit, J. Bruno, F. Kayal et al., “Saturated and unsaturated fatty acids differently modulate colonic goblet cells in vitro and in rat pups,” *Journal of Nutrition*, vol. 145, no. 8, pp. 1754–1762, 2015.
- [23] Y. Wan, Y. Fu, F. Wang, A. Sinclair, and D. Li, “Protective effects of a lipid extract from hard-shelled mussel (*Mytilus coruscus*) on intestinal integrity after lipopolysaccharide challenge in mice,” *Nutrients*, vol. 10, no. 7, p. 860, 2018.
- [24] P. C. Calder, N. Ahluwalia, R. Albers et al., “A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies,” *British Journal of Nutrition*, vol. 109, Suppl 1, pp. S1–S34, 2013.
- [25] S. Nordlander, J. Pott, and K. J. Maloy, “NLR4 expression in intestinal epithelial cells mediates protection against an enteric pathogen,” *Mucosal Immunology*, vol. 7, no. 4, pp. 775–785, 2014.
- [26] S. Zhao, Z. Gong, J. Zhou et al., “Deoxycholic acid triggers NLRP3 inflammasome activation and aggravates DSS-induced colitis in mice,” *Frontiers in Immunology*, vol. 7, p. 536, 2016.
- [27] E. Scaiola, E. Liverani, and A. Belluzzi, “The imbalance between n-6/n-3 polyunsaturated fatty acids and inflammatory bowel disease: a comprehensive review and future therapeutic perspectives,” *International Journal of Molecular Sciences*, vol. 18, no. 12, p. 2619, 2017.
- [28] M. T. Abreu, “Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function,” *Nature Reviews Immunology*, vol. 10, no. 2, pp. 131–144, 2010.
- [29] R. Ungaro, M. Fukata, D. Hsu et al., “A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis,” *American Journal of Physiology-Gastrointestinal and Liver Physiology*, vol. 296, no. 6, pp. G1167–G1179, 2009.
- [30] C. Luo and H. Zhang, “The role of proinflammatory pathways in the pathogenesis of colitis-associated colorectal cancer,” *Mediators of Inflammation*, vol. 2017, Article ID 5126048, 8 pages, 2017.
- [31] M. F. Neurath, “Cytokines in inflammatory bowel disease,” *Nature Review Immunology*, vol. 14, no. 5, pp. 329–342, 2014.
- [32] D. K. McDaniel, K. Eden, V. M. Ringel, and I. C. Allen, “Emerging roles for noncanonical NF- κ B signaling in the modulation of inflammatory bowel disease pathobiology,” *Inflammatory Bowel Diseases*, vol. 22, no. 9, pp. 2265–2279, 2016.
- [33] K. L. Honda, S. Lamon-Fava, N. R. Matthan, D. Wu, and A. H. Lichtenstein, “Docosahexaenoic acid differentially affects TNF α and IL-6 expression in LPS-stimulated RAW 264.7 murine macrophages,” *Prostaglandins, Leukotrienes, and Essential Fatty Acids*, vol. 97, pp. 27–34, 2015.
- [34] T. E. Novak, T. A. Babcock, D. H. Jho, W. S. Helton, and N. J. Espat, “NF- κ B inhibition by ω -3 fatty acids modulates LPS-stimulated macrophage TNF- α transcription,” *American*

- Journal of Physiology: Lung Cellular and Molecular Physiology*, vol. 284, no. 1, pp. L84–L89, 2003.
- [35] J. Miyamoto, T. Mizukure, S. B. Park et al., “A gut microbial metabolite of linoleic acid, 10-hydroxy-cis-12-octadecenoic acid, ameliorates intestinal epithelial barrier impairment partially via GPR40-MEK-ERK pathway,” *Journal of Biological Chemistry*, vol. 290, no. 5, pp. 2902–2918, 2015.
- [36] L. Dubuquoy, C. Rousseaux, X. Thuru et al., “PPAR γ as a new therapeutic target in inflammatory bowel diseases,” *Gut*, vol. 55, no. 9, pp. 1341–1349, 2006.
- [37] J. Bassaganya-Riera, K. Reynolds, S. Martino-Catt et al., “Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease,” *Gastroenterology*, vol. 127, no. 3, pp. 777–791, 2004.
- [38] R. Marion-Letellier, P. Dechelotte, M. Iacucci, and S. Ghosh, “Dietary modulation of peroxisome proliferator-activated receptor gamma,” *Gut*, vol. 58, no. 4, pp. 586–593, 2009.
- [39] J. Bassaganya-Riera, M. Viladomiu, M. Pedragosa et al., “Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR γ to suppress colitis,” *PLoS One*, vol. 7, no. 2, p. e31238, 2012.
- [40] J. Bassaganya-Riera, R. Hontecillas, W. T. Horne et al., “Conjugated linoleic acid modulates immune responses in patients with mild to moderately active Crohn’s disease,” *Clinical Nutrition*, vol. 31, no. 5, pp. 721–727, 2012.
- [41] R. Marion-Letellier, M. Butler, P. Déchelotte, R. J. Playford, and S. Ghosh, “Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells—potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation,” *American Journal of Clinical Nutrition*, vol. 87, no. 4, pp. 939–948, 2008.
- [42] E. Kvedaraitė, M. Lourda, M. Ideström et al., “Tissue-infiltrating neutrophils represent the main source of IL-23 in the colon of patients with IBD,” *Gut*, vol. 65, no. 10, pp. 1632–1641, 2016.
- [43] T. Gobetti, S. Ducheix, P. le Faouder et al., “Protective effects of n-6 fatty acids-enriched diet on intestinal ischaemia/reperfusion injury involve lipoxin A4 and its receptor,” *British Journal of Pharmacology*, vol. 172, no. 3, pp. 910–923, 2015.
- [44] A. Ibrahim, K. Mbodji, A. Hassan et al., “Anti-inflammatory and anti-angiogenic effect of long chain n-3 polyunsaturated fatty acids in intestinal microvascular endothelium,” *Clinical Nutrition*, vol. 30, no. 5, pp. 678–687, 2011.
- [45] A. B. Hawthorne, T. K. Daneshmend, C. J. Hawkey et al., “Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial,” *Gut*, vol. 33, no. 7, pp. 922–928, 1992.
- [46] H. Teague, B. D. Rockett, M. Harris, D. A. Brown, and S. R. Shaikh, “Dendritic cell activation, phagocytosis and CD69 expression on cognate T cells are suppressed by n-3 long-chain polyunsaturated fatty acids,” *Immunology*, vol. 139, no. 3, pp. 386–394, 2013.
- [47] L. H. Ly, R. Smith, K. C. Switzer, R. S. Chapkin, and D. N. McMurray, “Dietary eicosapentaenoic acid modulates CTLA-4 expression in murine CD4⁺ T-cells,” *Prostaglandins, Leukotrienes and Essential Fatty Acids*, vol. 74, no. 1, pp. 29–37, 2006.
- [48] Y. Tsuzuki, J. Miyazaki, K. Matsuzaki et al., “Differential modulation in the functions of intestinal dendritic cells by long and medium-chain fatty acids,” *Journal of Gastroenterology*, vol. 41, no. 3, pp. 209–216, 2006.
- [49] P. Krause, M. Bruckner, C. Uermösi, E. Singer, M. Groettrup, and D. F. Legler, “Prostaglandin E (2) enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells,” *Blood*, vol. 113, no. 11, pp. 2451–2460, 2009.
- [50] K. Arimoto-Miyamoto, N. Kadowaki, T. Kitawaki, S. Iwata, C. Morimoto, and T. Uchiyama, “Optimal stimulation for CD70 induction on human monocyte-derived dendritic cells and the importance of CD70 in naive CD4⁺ T-cell differentiation,” *Immunology*, vol. 130, no. 1, pp. 137–149, 2010.
- [51] T. Kanai and M. Watanabe, “Do fatty acids influence functions of intestinal dendritic cells?,” *Journal of Gastroenterology*, vol. 41, no. 3, pp. 288–289, 2006.
- [52] B. D. Rockett, M. Salameh, K. Carraway, K. Morrison, and S. R. Shaikh, “n-3 PUFA improves fatty acid composition, prevents palmitate-induced apoptosis, and differentially modifies B cell cytokine secretion in vitro and ex vivo,” *Journal of Lipid Research*, vol. 51, no. 6, pp. 1284–1297, 2010.
- [53] B. D. Rockett, H. Teague, M. Harris et al., “Fish oil increases raft size and membrane order of B cells accompanied by differential effects on function,” *Journal of Lipid Research*, vol. 53, no. 4, pp. 674–685, 2012.
- [54] E. A. Gurzell, H. Teague, M. Harris, J. Clinthorne, S. R. Shaikh, and J. I. Fenton, “DHA-enriched fish oil targets B cell lipid microdomains and enhances ex vivo and in vivo B cell function,” *Journal of Leukocyte Biology*, vol. 93, no. 4, pp. 463–470, 2013.
- [55] J. Kunisawa, E. Hashimoto, A. Inoue et al., “Regulation of intestinal IgA responses by dietary palmitic acid and its metabolism,” *Journal of Immunology*, vol. 193, no. 4, pp. 1666–1671, 2014.
- [56] L. Polese, R. Boetto, G. de Franchis et al., “B1a lymphocytes in the rectal mucosa of ulcerative colitis patients,” *World Journal of Gastroenterology*, vol. 18, no. 2, pp. 144–149, 2012.
- [57] M. Q. Rehman, D. Beal, Y. Liang et al., “B cells secrete eotaxin-1 in human inflammatory bowel disease,” *Inflammatory Bowel Diseases*, vol. 19, no. 5, pp. 922–933, 2013.
- [58] L. A. Zenewicz, A. Antov, and R. A. Flavell, “CD4 T-cell differentiation and inflammatory bowel disease,” *Trends in Molecular Medicine*, vol. 15, no. 5, pp. 199–207, 2009.
- [59] H. L. Woodworth, S. J. McCaskey, D. M. Duriancik et al., “Dietary fish oil alters T lymphocyte cell populations and exacerbates disease in a mouse model of inflammatory colitis,” *Cancer Research*, vol. 70, no. 20, pp. 7960–7969, 2010.
- [60] J. M. Monk, T. Y. Hou, H. F. Turk et al., “Dietary n-3 polyunsaturated fatty acids (PUFA) decrease obesity-associated Th17 cell-mediated inflammation during colitis,” *PLoS One*, vol. 7, no. 11, p. e49739, 2012.
- [61] J. M. Monk, Q. Jia, E. Callaway et al., “Th17 cell accumulation is decreased during chronic experimental colitis by (n-3) PUFA in Fat-1 mice,” *Journal of Nutrition*, vol. 142, no. 1, pp. 117–124, 2012.
- [62] D. Nagy-Szakai, S. A. V. Mir, R. A. Harris et al., “Loss of n-6 fatty acid induced pediatric obesity protects against acute murine colitis,” *FASEB Journal*, vol. 29, no. 8, pp. 3151–3159, 2015.
- [63] J. M. Monk, H. F. Turk, Y. Y. Fan et al., “Antagonizing arachidonic acid-derived eicosanoids reduces inflammatory Th17 and Th1 cell-mediated inflammation and colitis severity,”

- Mediators of Inflammation*, vol. 2014, Article ID 917149, 14 pages, 2014.
- [64] C. H. Huang, Y. C. Hou, M. H. Pai, C. L. Yeh, and S. L. Yeh, "Dietary ω -6/ ω -3 polyunsaturated fatty acid ratios affect the homeostasis of Th/Treg cells in mice with dextran sulfate sodium-induced colitis," *JPEN: Journal of Parenteral and Enteral Nutrition*, vol. 41, no. 4, pp. 647–656, 2017.
- [65] C. N. Serhan and N. A. Petasis, "Resolvins and protectins in inflammation resolution," *Chemical Reviews*, vol. 111, no. 10, pp. 5922–5943, 2011.
- [66] M. Arita, F. Bianchini, J. Aliberti et al., "Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1," *Journal of Experimental Medicine*, vol. 201, no. 5, pp. 713–722, 2005.
- [67] N. Chiang, J. Dalli, R. A. Colas, and C. N. Serhan, "Identification of resolvin D2 receptor mediating resolution of infections and organ protection," *Journal of Experimental Medicine*, vol. 212, no. 8, pp. 1203–1217, 2015.
- [68] I. M. Fierro, S. P. Colgan, G. Bernasconi et al., "Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic 15 epimers in chemotaxis and transmigration with microvessel endothelial cells and epithelial cells," *Journal of Immunology*, vol. 170, no. 5, pp. 2688–2694, 2003.
- [69] R. E. E. Abdulnour, J. Dalli, J. K. Colby et al., "Maresin 1 biosynthesis during platelet-neutrophil interactions is organ-protective," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 111, no. 46, pp. 16526–16531, 2014.
- [70] C. Maeyashiki, S. Oshima, Y. Nibe, M. Kobayashi, and M. Watanabe, "Mo1303 identification of autophagic regulators as therapeutic targets in intestinal epithelial cells," *Gastroenterology*, vol. 150, no. 4, pp. S692–S692, 2016.
- [71] C. Y. Chiu, B. Gomolka, C. Dierkes et al., "Omega-6 docosapentaenoic acid-derived resolvins and 17-hydroxydocosahexaenoic acid modulate macrophage function and alleviate experimental colitis," *Inflammation Research*, vol. 61, no. 9, pp. 967–976, 2012.
- [72] P. Prieto, C. E. Rosales-Mendoza, V. Terrón et al., "Activation of autophagy in macrophages by pro-resolving lipid mediators," *Autophagy*, vol. 11, no. 10, pp. 1729–1744, 2015.
- [73] C. Godson, S. Mitchell, K. Harvey, N. A. Petasis, N. Hogg, and H. R. Brady, "Cutting edge: lipoxins rapidly stimulate non-phlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages," *Journal of Immunology*, vol. 164, no. 4, pp. 1663–1667, 2000.
- [74] J. M. Schwab, N. Chiang, M. Arita, and C. N. Serhan, "Resolvin E1 and protectin D1 activate inflammation-resolution programmes," *Nature*, vol. 447, no. 7146, pp. 869–874, 2007.
- [75] S. Krishnamoorthy, A. Recchiuti, N. Chiang et al., "Resolvin D1 binds human phagocytes with evidence for proresolving receptors," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 4, pp. 1660–1665, 2010.
- [76] A. Ariel, G. Fredman, Y. P. Sun et al., "Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression," *Nature Immunology*, vol. 7, no. 11, pp. 1209–1216, 2006.
- [77] T. Hamabata, T. Nakamura, S. Masuko, S. Maeda, and T. Murata, "Production of lipid mediators across different disease stages of dextran sodium sulfate-induced colitis in mice," *Journal of Lipid Research*, vol. 59, no. 4, pp. 586–595, 2018.
- [78] A. F. Bento, R. F. Claudino, R. C. Dutra, R. Marcon, and J. B. Calixto, "Omega-3 fatty acid-derived mediators 17(R)-hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 prevent experimental colitis in mice," *Journal of Immunology*, vol. 187, no. 4, pp. 1957–1969, 2011.
- [79] R. Marcon, A. F. Bento, R. C. Dutra, M. A. Bicca, D. F. P. Leite, and J. B. Calixto, "Maresin 1, a proresolving lipid mediator derived from omega-3 polyunsaturated fatty acids, exerts protective actions in murine models of colitis," *Journal of Immunology*, vol. 191, no. 8, pp. 4288–4298, 2013.
- [80] A. P. Davenport, S. P. H. Alexander, J. L. Sharman et al., "International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands," *Pharmacological Reviews*, vol. 65, no. 3, pp. 967–986, 2013.
- [81] A. J. Bilotta and Y. Cong, "Gut microbiota metabolite regulation of host defenses at mucosal surfaces: implication in precision medicine," *Precision Clinical Medicine*, vol. 2, no. 2, pp. 110–119, 2019.
- [82] M. Pizzonero, S. Dupont, M. Babel et al., "Discovery and optimization of an azetidine chemical series as a free fatty acid receptor 2 (FFA2) antagonist: from hit to clinic," *Journal of Medicinal Chemistry*, vol. 57, no. 23, pp. 10044–10057, 2014.
- [83] A. T. Suckow and C. P. Briscoe, "Key questions for translation of FFA receptors: from pharmacology to medicines," *Handbook of Experimental Pharmacology*, vol. 236, pp. 101–131, 2017.
- [84] C. F. Burant, P. Viswanathan, J. Marcinak et al., "TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial," *Lancet*, vol. 379, no. 9824, pp. 1403–1411, 2012.
- [85] D. S. Im, "FFA4 (GPR120) as a fatty acid sensor involved in appetite control, insulin sensitivity and inflammation regulation," *Molecular Aspects of Medicine*, vol. 64, pp. 92–108, 2018.
- [86] J. M. Kim, K. P. Lee, S. J. Park et al., "Omega-3 fatty acids induce Ca²⁺ mobilization responses in human colon epithelial cell lines endogenously expressing FFA4," *Acta Pharmacologica Sinica*, vol. 36, no. 7, pp. 813–820, 2015.